Eyenovia stock plummets following Phase III myopia trial failure

By Yahoo! Finance | Nov 18, 2024 at 07:38 AM EST

Eyenovia's stock price dropped significantly by more than two-thirds due to the failure of its Phase III study for myopia treatment. The CHAPERONE trial did not meet its primary endpoint, leading the company to consider strategic options to preserve its value.

Did you find this insightful?

Bad

Just Okay

Amazing

We are preparing, please wait

New Alert

Select an alert type

Sentiment Spike

Send email alert if news sentiment changes significantly

Mentions Spike

Send email alert if has a surge in mentions

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.